

**LightDeck Diagnostics**


(Previously MBio Diagnostics, Inc.)



Boulder, CO 80303

<https://LightDeckDx.com/>

(303) 952-2905

**SINCE ITS FOUNDING IN****2009****8 SBIR Awards****75 Employees****N/A Socioeconomic Status****6 US Patents from SBIR/STTR****Host-Response Panels at the Point-of-Care**

Lab methods used to assess severe infections are slow and costly. Speed and quality matter in diagnosing and treating sepsis and COVID-19. High quality, fast and simple point-of-care tests are sorely needed to improve outcomes and costs.

The LightDeck platform is built on advanced planar waveguide technology that uses inexpensive, disposable test cartridges and a portable analyzer.

- **Quality:** Highly sensitive tests that deliver lab-quality results
- **Quick:** Actionable results in as little as 5 minutes
- **Quantitative:** More data to inform treatment decisions
- **Multiplex:** Multiple tests per sample plus internal

The prototype host-response system was successfully deployed to the DoD's Uniformed Services University in collaboration with the Henry Jackson Foundation. The demonstration focused on rapid detection of IL-6 during COVID infection.

As part of its ongoing strategy to expand into human clinical diagnostics testing, company name was recently changed from MBio Diagnostics to LightDeck Diagnostics.

**IMPACT**

The LightDeck platform enables lab-quality testing almost anywhere, from the emergency department to ICU to low-resource settings. Know-how from the host-response programs have been applied to products for COVID-19, cardiac markers to assess chest pain and other IVD products.

**Phase II Accomplishments**

The COVID-19 Total Antibody Test, funded in part under a BARDA contract of \$629,595, is now available through the FDA Emergency Use Authorization (EUA) process. The Company has raised >\$60M in venture funding and federal contracts, including \$1.8M for two projects with NOAA. Platform technology developed under the DARPA SBIR was the basis of the company's veterinary product commercialization.

**Solicitation:**

*Point-of-care Monitoring of the Host-Pathogen Interaction during Infection*

**DARPA SBIR Sponsor****SB162-002 Topic Number****Improved Performance Primary Innovation****Greater Reliability Secondary Innovation**